MCMorgane Cellier

Morgane Cellier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Morgane Cellier has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intentional xylazine poisoning: a nationwide French poison control center study

    by Olivier Denis, Amandine Douvinet, Bruno Mégarbane, Jérôme Langrand, Morgane Cellier, Laurène Dufayet, Christine Tournoud, Emmanuel Puskarczyk, Nicolas Franchitto, Fanny Pelissier, et al.

    Xylazine, an α2-adrenergic agonist used as a veterinary sedative, has emerged as an adulterant of illicit opioids, contributing to fatal overdoses in North America and has recently been detected in Europe. In France, despite alarmist media reports, data on xylazine exposures are scarce. We retrospectively reviewed intentional xylazine exposures reported to the eight French poison control centers from January 2010 to December 2024. Cases were extracted from the French National Database of Poisonings. Inclusion required intentional use; severity was assessed using the Poison Severity Score. Nineteen intentional exposures were identified: seventeen in the context of a suicide attempt, one homicidal, and one recreational. Mean age was 36.4 years; sex ratio 2.6 (male/female). For the cases occurring in the context of a suicide attempt, eleven involved xylazine alone, and six in combination with other drugs (mainly ketamine or fentanyl). Three fatalities occurred (16%), and six patients developed severe clinical features (Poisoning Severity Score 3), including coma, bradycardia, and hypotension. The single recreational case involved a fentanyl/xylazine mixture with full recovery. Over a 14-year period, intentional xylazine poisonings reported to French Poison Control Centers were uncommon, mainly occurring in the context of a suicide attempt, and often linked to occupational access to veterinary sedatives. These data do not support community or recreational spread. Nonetheless, observed cases confirm xylazine's life-threatening potential. This retrospective analysis highlights the rarity of reported xylazine exposures in French poison centre data, strengthened toxicological surveillance and coordination between Poison Control Center and drug-checking networks are needed to detect any shift toward broader use and guide prevention efforts.

  • Tropatepine poisoning and management: a series of 458 cases

    by Emilie Tireau, Alexis Descatha, Marie Deguigne, Nathalie Paret, Cécile Chevallier, Anthony Facile, Aurore Czerwiec, Ramy Azzouz, Anne Garat, Patrick Nisse, et al.

    Tropatepine is an antiparkinsonian drug that can be associated with antimuscarinic delirium in overdose. Two acetylcholinesterase inhibitors, neostigmine and physostigmine, are available for the management of tropatepine poisoning. The aim of this study is to describe a series of tropatepine poisonings and to compare the management of patients. This epidemiological, retrospective, multicentre study reviewed tropatepine intoxications reported to French poison centres from 1 January 2000 to 13 July 2023. The relationship between reduction in central antimuscarinic signs and associated risk factors was assessed by univariate and multivariate logistic regression. A total of 458 cases of tropatepine poisoning were included. Peripheral and central antimuscarinic signs were observed in 214 (46.7%) and 102 patients (22.3%), respectively. For patients who ingested tropatepine alone (n = 94), 29 (30.8%) showed agitation or delirium. A reported median ingested dose of 270 mg of tropatepine was associated with the onset of central and peripheral antimuscarinic signs, compared with 100 mg for peripheral signs alone (P = 0.0012). The median (IQR) duration of central antimuscarinic signs was 24 h (12-48 h). Agitation was treated by neostigmine and physostigmine in 25 and 13 patients, respectively. In 16 (76%) patients treated with neostigmine, there was no improvement in central signs, whereas 13 (100%) patients responded favorably to physostigmine. After adjustment for ingested dose, the complete resolution of central antimuscarinic signs was significantly higher in patients treated with physostigmine than with neostigmine (odds ratio 6.61; 95% CI: 1.00-44.94]; P = 0.0499). Due to its long elimination half-life, tropatepine poisoning is frequently associated with a severe and prolonged antimuscarinic syndrome. Caring for these agitated patients requires substantial input from nursing staff. Physostigmine is still little used but appears to be effective in controlling the central antimuscarinic syndrome induced by tropatepine.

  • Body packers and body stuffers: cocaine intoxications reported to French poison centers (January 1, 2020—December 31, 2024)

    by Katharina von Fabeck, Mathieu Glaizal, Nicolas Simon, Fabien Genestier, Cécile Chevallier, Aurore Gouraud, Giuseppe Balice, Ramy Azzouz, Anne Garat, Patrick Nisse, et al.

    Cocaine use has increased significantly over the past three decades. This study aimed to analyze cases of cocaine intoxication involving body packing and body stuffing, focusing on symptomatology, treatment, and clinical outcomes. A retrospective analysis was performed of cases of cocaine poisoning recorded in the French national poison center database over a five-year period (2020-2024). Extracted data included demographics, amount and route of cocaine concealment, number of pellets, clinical presentation, management, outcomes, location of arrest, and packaging type. An ordinal logistic regression was conducted to identify factors associated with poisoning severity, using the Poisoning Severity Score as the dependent variable. Among 2,534 cases of cocaine intoxication, 146 involved body packers or body stuffers: 73 body packers and 73 body stuffers. The male-to-female ratio for body packers was 3.3:1, and for body stuffers, it was 72:1, with only one female. The median age of body packers was 25.5 years (range: 17-62 years) and for body stuffers, 28.2 years (range: 16-58 years). Body packers ingested between one and 190 pellets, while body stuffers ingested between one and ten pellets, each containing cocaine 1-15 g. Symptoms included gastrointestinal, cardiovascular, neurological, and respiratory effects. One death occurred among body packers, and two among body stuffers. Age was a significant predictor of severity, with older individuals at higher risk of severe outcomes. Cocaine intoxication in body packers and stuffers presents serious health risks. Body packers ingested larger quantities with more secure packaging, while body stuffers ingested smaller amounts but used less secure methods, often due to law enforcement urgency. Despite differences in ingestion patterns, both groups showed similar symptoms, with older body packers more likely to experience severe effects. While severe complications were rare, cocaine intoxication in both body packers and stuffers can be fatal, highlighting ongoing public health risks related to cocaine trafficking and the need for timely medical intervention.


  • Open Access

    Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database

    by Morgane Cellier, Delphine Bourneau-Martin, Chadi Abbara, Alexandre Crosnier, Laurence Lagarce, Anne-Sophie Garnier, Marie Briet

    Background: Alongside their BCR-ABL specificity, TKIs used in chronic myeloid leukemia also target other tyrosine kinases expressed in the kidney such as PDGFR, c-KIT, SRC, and VEGFR, which may result in specific renal adverse drug reaction (ADR). To evaluate the renal safety profile in real-life conditions, a case/non-case study was performed on VigiBase®, the WHO global safety database. Methods: From 7 November 2001 to 2 June 2021, all cases in which the involvement of imatinib, dasatinib, nilotinib, bosutinib, and ponatinib was suspected in the occurrence of renal ADR were extracted from VigiBase®. Disproportionality analyses were assessed using the reporting odds ratio. Results: A total of 1409 cases were included. Imatinib accounts for half of the reported cases. A signal of disproportionate reporting (SDR) of renal failure and fluid retention was found for the five TKIs. Only dasatinib and nilotinib were related to an SDR for nephrotic syndrome. Nilotinib and ponatinib were related to an SDR for renal artery stenosis, while dasatinib was related to an SDR for thrombotic microangiopathy. No SDR for tubulointerstitial nephritis was observed. Conclusion: This study identified a new safety signal, nephrotic syndrome, for nilotinib and highlights the importance of post-marketing safety surveillance.


  • Comment on: amanitin intoxication

    by Morgane Cellier, Jérémy Lecot, Chloe Bruneau, Marie Deguigne, Marc Fadel, Gaël Le Roux, Alexis Descatha

    Dear Editor,We have read with interest the paper “Amanitin intoxication: effects of therapies on clinical outcomes – a review of 40 years of reported cases” [1].There are no worldwide accepted guid...


  • Open Access

    Temporal trends in calls for suicide attempts to poison control centers in France during the COVID-19 pandemic: a nationwide study

    by Fabrice Jollant, Ingrid Blanc-Brisset, Morgane Cellier, Marine Ambar Akkaoui, Viet Chi Tran, Jean-François Hamel, Marie-Aude Piot, Mikail Nourredine, Patrick Nisse, The French Poison Center Control Research Group, et al.

    Concerns have been raised about early vs. later impacts of the COVID-19 pandemic on suicidal behavior. However, data remain sparse to date. We investigated all calls for intentional drug or other toxic ingestions to the eight Poison Control Centers in France between 1st January 2018 and 31st May 2022. Data were extracted from the French National Database of Poisonings. Calls during the study period were analyzed using time trends and time series analyses with SARIMA models (based on the first two years). Breakpoints were determined using Chow test. These analyses were performed together with examination of age groups (≤ 11, 12–24, 25–64, ≥ 65 years) and gender effects when possible. Over the studied period, 66,589 calls for suicide attempts were received. Overall, there was a downward trend from 2018, which slowed down in October 2019 and was followed by an increase from November 2020. Number of calls observed during the COVID period were above what was expected. However, important differences were found according to age and gender. The increase in calls from mid-2020 was particularly observed in young females, while middle-aged adults showed a persisting decrease. An increase in older-aged people was observed from mid-2019 and persisted during the pandemic. The pandemic may therefore have exacerbated a pre-existing fragile situation in adolescents and old-aged people. This study emphasizes the rapidly evolving situation regarding suicidal behaviour during the pandemic, the possibility of age and gender differences in impact, and the value of having access to real-time information to monitor suicidal acts.


  • Determination of Glyphosate and AMPA in Blood Can Predict the Severity of Acute Glyphosate Herbicide Poisoning

    by M Cellier, N Anthony, C Bruneau, A Descatha

    Objective: To evaluate a potential association between blood and urine concentration of glyphosate and its metabolite, aminomethylphosphonic acid (AMPA), with severity of acute glyphosate (herbicide) poisoning. Methods: In our retrospective study of acute glyphosate poisoning, we examined records from the French National Database of Poisonings, dated between January 1, 2004, and December 31, 2016. We compared the severity of poisoning among case individuals using the Fisher exact test and Wilcoxon test. Also, we calculated ROC curves to determine the cutoff for blood and urine concentration. Results: A total of 17 plasma glyphosate, 11 urine glyphosate, 13 plasma AMPA, and 10 urine AMPA specimens were included in our study, with collection dates ranging from January 1, 2004, through December 31, 2016. Conclusion: The optimal cutoff we discovered for blood concentration of AMPA was 0.88 mg/L; for glyphosate, it was 600 mg/L. The cutoff plasma concentration of AMPA has never been described in the literature, to our knowledge.


  • Open Access

    Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase® the WHO Global Database of Individual Case Safety Reports

    by Alexandre Crosnier, Chadi Abbara, Morgane Cellier, Laurence Lagarce, Marina Babin, Delphine Bourneau-Martin, Marie Briet

    Kidney EGFR expression together with reported cases of glomerular diseases in the context of anti-EGFR drug administration raise concerns about the renal safety profile of these drugs. This issue is addressed in a case/non-case study carried out on VigiBase®, the WHO global database of individual case safety reports (ICRS). Disproportionality analysis of renal adverse effects related to the selected anti-EGFR drugs, erlotinib, gefitinib, afatinib, osimertinib, cetuximab and panitumumab, was assessed using the reporting odds ratio (ROR). Nine hundred and eighty-nine ICRSs were included. A signal of disproportionate reporting (SDR) was found for afatinib (ROR = 2.70; 95% CI [2.22–3.29]) and erlotinib (ROR = 1.73; 95% CI [1.46–2.04]) with acute kidney injury, and for afatinib (ROR = 2.41; 95% CI [1.78–3.27]), cetuximab (ROR = 1.42; 95% CI [1.14–1.78]) and erlotinib (ROR = 2.23; 95% CI [1.80–2.77]) with renal failure. The preferred term “diarrhoea” was frequently reported in the included cases. An SDR was found for erlotinib with haemolytic and uremic syndrome (ROR = 4.01; 95% CI [1.80–8.94]) and thrombotic microangiopathy (ROR = 4.94; 95% CI [2.80–8.72]). No SDR was seen for glomerular or tubule-interstitial diseases. This study showed that the anti-EGFR drug renal toxicity is mainly related to renal failure in the context of digestive toxicity.


  • Open Access

    Dairy goats adjust their meal patterns to the fibre content of the diet

    by B.L. Nielsen, M. Cellier, C. Duvaux-Ponter, S. Giger-Reverdin